MARKET

HALO

HALO

Halozyme Thrp
NASDAQ
39.54
+0.02
+0.05%
After Hours: 39.54 0 0.00% 17:00 09/30 EDT
OPEN
39.73
PREV CLOSE
39.52
HIGH
40.58
LOW
39.28
VOLUME
1.92M
TURNOVER
0
52 WEEK HIGH
52.98
52 WEEK LOW
31.36
MARKET CAP
5.45B
P/E (TTM)
15.66
1D
5D
1M
3M
1Y
5Y
We Ran A Stock Scan For Earnings Growth And Halozyme Therapeutics (NASDAQ:HALO) Passed With Ease
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Simply Wall St. · 09/21 14:43
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection
Argenx SE (NASDAQ: ARGX) has 
Benzinga · 09/21 13:58
Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod
Argenx (NASDAQ:ARGX) <a href="https://seekingalpha.com/pr/18946995-arge...
Seekingalpha · 09/21 09:50
Morgan Stanley Initiates Coverage On Halozyme Therapeutics with Overweight Rating, Announces Price Target of $50
Morgan Stanley analyst Andrew Galler initiates coverage on Halozyme Therapeutics (NASDAQ:HALO) with a Overweight rating and announces Price Target of $50.
Benzinga · 09/09 11:51
Morgan Stanley Initiates Halozyme Therapeutics at Overweight Rating With $50 Price Target
Morgan Stanley Initiates Halozyme Therapeutics at Overweight Rating With $50 Price Target
MT Newswires · 09/09 09:44
Halozyme Therapeutics (HALO) Down 10.6% Since Last Earnings Report: Can It Rebound?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/08 15:30
BRIEF-Halozyme Therapeutics Entered Into Amendment No. 1 To Credit Agreement
BRIEF-Halozyme Therapeutics Entered Into Amendment No. 1 To Credit Agreement
Reuters · 08/19 21:28
Halozyme Therapeutics raises $625M through convertible senior notes due 2028
Halozyme Therapeutics (NASDAQ:HALO) has <a href="https://see...
Seekingalpha · 08/16 09:40
More
About HALO
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. The rHuPH20 can be applied as a drug delivery platform to increase dispersion and absorption of other injected drugs and fluids, potentially reducing the treatment burden.

Webull offers kinds of Halozyme Therapeutics, Inc. stock information, including NASDAQ:HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.